A Safety and Tolerability Study of INCAGN02390 in Select Advanced Malignancies

Conditions:   Cervical Cancer;   Gastric Cancer (Including Stomach and Gastroesophageal Junction);   Esophageal Cancer;   Hepatocellular Carcinoma;   Melanoma (Uveal Melanoma Excluded);   Merkel Cell Carcinoma;   Mesothelioma;   Microsatellite Instability (MSI)-High/ Deficient Mismatch Repair (dMMR) Tumors;   Non-small Cell Lung Cancer (NSCLC);   Ovarian Cancer;   Squamous Cell Carcinoma of the Head and Neck;   Small Cell Lung Cancer;   Renal Cell Carcinoma (RCC);   Triple-negative Breast Cancer;   Urothelial Carcinoma
Intervention:   Drug: INCAGN02390
Sponsor:   Incyte Corporation
Not yet recruiting

https://ift.tt/2MAwPVs